HER2 testing in gastric cancer: An update

World Journal of Gastroenterology

Volumn 22, Issue 19, 2016, Pages 4619-4625

  Lucas, Faria Abrahao Machado ^a   Cristovam, Scapulatempo Neto ^a  

^a BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Gastric cancer; Human epidermal growth factor receptor 2 testing; Immunohistochemistry; Scoring system; Trastuzumab

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULARLY TARGETED THERAPY; PATIENT SELECTION; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; STOMACH CANCER; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION; GENETICS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; ESOPHAGOGASTRIC JUNCTION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84977631930     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i19.4619     Document Type: Review

References (41)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646 [PMID: 3012781 DOI:10.1126/science.3012781].
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182 [PMID: 3798106 DOI:10.1126/science.3798106].
3. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: Review of results from 37, 992 patients. Cancer Metastasis Rev 2015; 34: 157-164 [PMID: 25712293 DOI:10.1007/s10555-015-9552-6].
4. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013; 19: 2171-2178 [PMID: 23599643 DOI:10.3748/wjg.v19.i14.2171].
5. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662 [PMID: 22689179].
6. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg 2015; 19: 1565-1571 [PMID: 26179664].
7. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, Mori M, Doki Y. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 2015; 18: 691-697 [PMID: 25224659].
8. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. C-ERBB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumorassociated protease systems. J Clin Oncol 2000; 18: 2201-2209 [PMID: 10829039].
9. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134].
10. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1, 414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18: 2833-2840 [PMID: 21468783 DOI:10.1245/s10434-011-1695-2].
11. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379 [PMID: 16868827 DOI:10.1007/s10620-005-9057-1].
12. Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu overexpression on prognosis in gastric cancer: A meta-analysis. Asian Pac J Cancer Prev 2011; 12: 1417-1423 [PMID: 22229170].
13. Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol 2013; 19: 6438-6446 [PMID: 24151362 DOI:10.3748/wjg.v19.i38.6438].
14. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 2012; 3: 137-144 [PMID: 22481979 DOI:10.7150/jca.4090].
15. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51 [PMID: 17611206 DOI:10.1056/NEJMra043186].
16. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI:10.1016/S0140-6736(10)61121-X].
17. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307 [PMID: 20665045].
18. Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015; 18: 476-484 [PMID: 25038874].
19. Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer 2014; 111: 660-666 [PMID: 24960402 DOI:10.1038/bjc.2014.356].
20. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study. J Clin Oncol 2014; 32: 2039-2049 [PMID: 24868024 DOI:10.1200/JCO.2013.53.6136].
21. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-179 [PMID: 21458915 DOI:10.1016/j.canlet.2011.03.002].
22. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22: 2403-2414 [PMID: 26937129 DOI:10.3748/wjg.v22.i8.2403].
23. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol 2016; Epub ahead of print [PMID: 26925958].
24. Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases 2015; 3: 42-51 [PMID: 25610849 DOI:10.12998/wjcc.v3.i1.42].
25. Wong DD, de Boer WB, Platten MA, Jo VY, Cibas ES, Kumarasinghe MP. HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol 2015; 43: 80-85 [PMID: 25363414 DOI:10.1002/dc.23212].
26. Manion E, Hornick JL, Lester SC, Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol 2011; 135: 845-851 [PMID: 21571957 DOI:10.1309/AJCPIP5LOO3NGDJG].
27. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71 [PMID: 16328035 DOI:10.3892/or.15.1.65].
28. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000; 113: 852-859 [PMID: 10874886 DOI:10.1309/VACPVLQA-G9DX-VUDF].
29. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 383-394 [PMID: 21323962 DOI:10.1111/j.1365-2559.2011.03760.x].
30. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-59 [PMID: 21169738 DOI:10.1097/PAP.0b013e3182026d72].
31. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, Kölble K, Kristiansen G. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007; 451: 19-25 [PMID: 17562074].
32. Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silverenhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011; 24: 794-800 [PMID: 21317877].
33. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: 822-831 [PMID: 22092393 DOI:10.1111/j.1365-2559.2011.04012.x].
34. Cho EY, Park K, Do I, Cho J, Kim J, Lee J, Kim S, Kim KM, Sohn TS, Kang WK, Kim S. Heterogeneity of ERBB2 in gastric carcinomas: A study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol 2013; 26: 677-684 [PMID: 23238628].
35. Sitas F. Twenty five years since the first prospective study by Forman et al. (1991) on Helicobacter pylori and stomach cancer risk. Cancer Epidemiol 2016; 41: 159-164 [PMID: 26922171].
36. Tegtmeyer N, Zabler D, Schmidt D, Hartig R, Brandt S, Backert S. Importance of EGF receptor, HER2/Neu and Erk1/2 kinase signalling for host cell elongation and scattering induced by the Helicobacter pylori CagA protein: Antagonistic effects of the vacuolating cytotoxin VacA. Cell Microbiol 2009; 11: 488-505 [PMID: 19046339].
37. Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol 2015; 141: 1343-1351 [PMID: 25544671 DOI:10.1007/s00432-014-1900-3].
38. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI:10.1111/j.1365-2559.2008.03028.x].
39. Huang SC, Ng KF, Lee SE, Chen KH, Yeh TS, Chen TC. HER2 testing in paired biopsy and excision specimens of gastric cancer: The reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer 2016; 19: 176-182 [PMID: 25512144].
40. Ahn S, Ahn S, Van Vrancken M, Lee M, Ha SY, Lee H, Min BH, Lee JH, Kim JJ, Choi S, Jung SH, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim KM. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget 2015; 6: 38372-38380 [PMID: 26460823].
41. Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, Kim S. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012; 44: 216-220 [PMID: 22437741 DOI:10.1097/PAT.0b013e3283513e8b].